Eur Urol Oncol
-
Publication Venue For
- Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics.. 5:265-267. 2022
- Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel.. 5:18-29. 2022
- Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial.. 4:948-954. 2021
- Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503).. 4:543-552. 2021
- A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.. 4:464-472. 2021
- Data-driven Focal Therapy for Localized Prostate Cancer: A Wake-up Call.. 4:424-425. 2021
- Diet and Exercise Are not Associated with Skeletal Muscle Mass and Sarcopenia in Patients with Bladder Cancer.. 4:237-245. 2021
- The Cost to Medicare of Bladder Cancer Care.. 3:515-522. 2020
- Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis.. 3:318-340. 2020
- Rare Germline Pathogenic Mutations of DNA Repair Genes Are Most Strongly Associated with Grade Group 5 Prostate Cancer.. 3:224-230. 2020
- Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.. 2:677-684. 2019
- Diagnosis and Management of Local Recurrence After Prostate Focal Therapy: Challenges and Solutions.. 2:539-540. 2019
- Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer.. 1:151-159. 2018